API | interferon alfacon-1

interferon alfacon-1 (Infergen) Report issue

Biologics Recombinant protein Approved ^FDA

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Interferon alfacon-1 is a recombinant synthetic type I interferon used for the treatment of hairy cell leukemia, malignant melanoma and AIDS-related Kaposi's sarcoma. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
interferon alfacon-1

More Chemistry

Pharmacology

Mechanisms of Action:
- Interferon alpha/beta receptor 1 (Homo sapiens) ^UniProt
- Interferon alpha/beta receptor 2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Yes
Availability: Discontinued
Delivery Methods: Parenteral
Pro Drug: No

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Hepatitis C (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (6)

COVID-19 (Phase 2)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 3)

Influenza, Human (Phase 1/Phase 2)

Interferons (Phase 2)

Nebulizers and Vaporizers (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue